QDVG:F:F-iShares S&P 500 Health Care Sector UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 10.742

Change

-0.02 (-0.17)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.74 (+2.78%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+1.29 (+2.56%)

USD 109.59B
SXR8:F iShares Core S&P 500 UCITS ETF..

-1.80 (-0.33%)

USD 96.22B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+1.47 (+2.68%)

USD 91.00B
SXRZ:F iShares VII PLC - iShares Nikk..

+6.60 (+2.79%)

USD 54.70B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.24 (+1.55%)

USD 52.21B
VUAA:F Vanguard S&P 500 UCITS Acc

N/A

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.04 (-0.52%)

USD 40.38B
0ZC:F Zscaler Inc

+1.02 (+0.66%)

USD 37.92B

ETFs Containing QDVG:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.05% 63% D 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.05% 59% D- 57% F
Trailing 12 Months  
Capital Gain 14.83% 56% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.83% 53% F 54% F
Trailing 5 Years  
Capital Gain 80.20% 89% A- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.20% 89% A- 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 12.17% 81% B- 74% C
Dividend Return 12.17% 79% B- 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.06% 62% D 86% B+
Risk Adjusted Return 110.04% 99% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike